Cargando…

Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer

We present a case of a 56-year-old male patient with stage IIIB (T3N2M0) poorly differentiated squamous cell carcinoma of the lung. Four cycles of chemotherapy were first applied, and the patient had stable disease. However, the patient refused to receive radiotherapy, therefore second-line treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Hengrui, Deng, Hongsheng, Liang, Wenhua, Guo, Kai, Gao, Ziqing, Wiesel, Ory, Flores, Raja M., Song, Kimberly, Redwan, Bassam, Migliore, Marcello, Li, Shuben, Yin, Weiqiang, He, Jianxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154428/
https://www.ncbi.nlm.nih.gov/pubmed/32309392
http://dx.doi.org/10.21037/atm.2020.01.118
_version_ 1783521815280222208
author Liang, Hengrui
Deng, Hongsheng
Liang, Wenhua
Guo, Kai
Gao, Ziqing
Wiesel, Ory
Flores, Raja M.
Song, Kimberly
Redwan, Bassam
Migliore, Marcello
Li, Shuben
Yin, Weiqiang
He, Jianxing
author_facet Liang, Hengrui
Deng, Hongsheng
Liang, Wenhua
Guo, Kai
Gao, Ziqing
Wiesel, Ory
Flores, Raja M.
Song, Kimberly
Redwan, Bassam
Migliore, Marcello
Li, Shuben
Yin, Weiqiang
He, Jianxing
author_sort Liang, Hengrui
collection PubMed
description We present a case of a 56-year-old male patient with stage IIIB (T3N2M0) poorly differentiated squamous cell carcinoma of the lung. Four cycles of chemotherapy were first applied, and the patient had stable disease. However, the patient refused to receive radiotherapy, therefore second-line treatment chemotherapy combined with anti-PD-1 immunotherapy was applied. Partial response was reached at the 4(th) cycle of chemotherapy combined with anti-PD-1 immunotherapy. The neoadjuvant strategy was prolonged to 10 cycles but no significant change was observed on tumor size. The patient then underwent video-assisted thoracoscopic left lower lobectomy. Eight cycles of adjuvant PD-1 immunotherapy were applied postoperatively. Perioperative immunotherapy demonstrated good curative effect in this patient and no recurrence was observed at the clinic 40 months following surgery. Here we intend to explore the concept of immunotherapy combined with chemotherapy and surgery in neoadjuvant and adjuvant setting, and to investigate the possibility of extending this strategy in patients with stage IIIB non-small cell lung cancer (NSCLC).
format Online
Article
Text
id pubmed-7154428
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-71544282020-04-17 Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer Liang, Hengrui Deng, Hongsheng Liang, Wenhua Guo, Kai Gao, Ziqing Wiesel, Ory Flores, Raja M. Song, Kimberly Redwan, Bassam Migliore, Marcello Li, Shuben Yin, Weiqiang He, Jianxing Ann Transl Med iMDT Corner We present a case of a 56-year-old male patient with stage IIIB (T3N2M0) poorly differentiated squamous cell carcinoma of the lung. Four cycles of chemotherapy were first applied, and the patient had stable disease. However, the patient refused to receive radiotherapy, therefore second-line treatment chemotherapy combined with anti-PD-1 immunotherapy was applied. Partial response was reached at the 4(th) cycle of chemotherapy combined with anti-PD-1 immunotherapy. The neoadjuvant strategy was prolonged to 10 cycles but no significant change was observed on tumor size. The patient then underwent video-assisted thoracoscopic left lower lobectomy. Eight cycles of adjuvant PD-1 immunotherapy were applied postoperatively. Perioperative immunotherapy demonstrated good curative effect in this patient and no recurrence was observed at the clinic 40 months following surgery. Here we intend to explore the concept of immunotherapy combined with chemotherapy and surgery in neoadjuvant and adjuvant setting, and to investigate the possibility of extending this strategy in patients with stage IIIB non-small cell lung cancer (NSCLC). AME Publishing Company 2020-03 /pmc/articles/PMC7154428/ /pubmed/32309392 http://dx.doi.org/10.21037/atm.2020.01.118 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle iMDT Corner
Liang, Hengrui
Deng, Hongsheng
Liang, Wenhua
Guo, Kai
Gao, Ziqing
Wiesel, Ory
Flores, Raja M.
Song, Kimberly
Redwan, Bassam
Migliore, Marcello
Li, Shuben
Yin, Weiqiang
He, Jianxing
Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer
title Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer
title_full Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer
title_fullStr Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer
title_full_unstemmed Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer
title_short Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer
title_sort perioperative chemoimmunotherapy in a patient with stage iiib non-small cell lung cancer
topic iMDT Corner
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154428/
https://www.ncbi.nlm.nih.gov/pubmed/32309392
http://dx.doi.org/10.21037/atm.2020.01.118
work_keys_str_mv AT lianghengrui perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT denghongsheng perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT liangwenhua perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT guokai perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT gaoziqing perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT wieselory perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT floresrajam perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT songkimberly perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT redwanbassam perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT miglioremarcello perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT lishuben perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT yinweiqiang perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer
AT hejianxing perioperativechemoimmunotherapyinapatientwithstageiiibnonsmallcelllungcancer